Medtronic PLC $MDT Shares Acquired by Capital Analysts LLC

Key Points

• Capital Analysts LLC has increased its holdings in Medtronic PLC by 7.8% during the first quarter, now owning 130,732 shares worth approximately $11.75 million.
• Medtronic's latest quarterly earnings report revealed $1.26 EPS, surpassing estimates and reflecting a 7.7% increase in revenue year-over-year.
• The company recently announced a quarterly dividend of $0.71 per share, which corresponds to an annual yield of 3.2% based on the current share price.

Capital Analysts LLC raised its position in Medtronic PLC (NYSE:MDT - Free Report) by 7.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 130,732 shares of the medical technology company's stock after purchasing an additional 9,432 shares during the quarter. Capital Analysts LLC's holdings in Medtronic were worth $11,748,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Dunhill Financial LLC lifted its stake in Medtronic by 17.2% in the first quarter. Dunhill Financial LLC now owns 847 shares of the medical technology company's stock valued at $76,000 after buying an additional 124 shares during the last quarter. Cidel Asset Management Inc. grew its position in shares of Medtronic by 1.3% during the first quarter. Cidel Asset Management Inc. now owns 9,531 shares of the medical technology company's stock worth $856,000 after acquiring an additional 126 shares during the last quarter. Petros Family Wealth LLC increased its holdings in shares of Medtronic by 4.3% in the 1st quarter. Petros Family Wealth LLC now owns 3,111 shares of the medical technology company's stock valued at $280,000 after acquiring an additional 127 shares during the period. Motco raised its position in Medtronic by 27.0% in the 1st quarter. Motco now owns 635 shares of the medical technology company's stock valued at $57,000 after purchasing an additional 135 shares during the last quarter. Finally, Baker Avenue Asset Management LP raised its position in Medtronic by 3.1% in the 1st quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company's stock valued at $410,000 after purchasing an additional 136 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDT has been the subject of several research reports. Royal Bank Of Canada reduced their price target on shares of Medtronic from $105.00 to $101.00 and set an "outperform" rating for the company in a research report on Thursday, May 22nd. Wall Street Zen downgraded shares of Medtronic from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. William Blair upgraded shares of Medtronic to a "hold" rating in a research report on Friday, July 11th. Needham & Company LLC reiterated a "hold" rating on shares of Medtronic in a research report on Thursday, August 14th. Finally, BTIG Research reiterated a "neutral" rating on shares of Medtronic in a research report on Friday, July 11th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $101.15.

Medtronic Stock Performance

Medtronic stock traded up $1.5210 during trading hours on Friday, reaching $92.6210. 4,870,626 shares of the stock were exchanged, compared to its average volume of 7,618,189. The stock has a market cap of $118.72 billion, a P/E ratio of 25.52, a P/E/G ratio of 2.31 and a beta of 0.80. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.42 and a current ratio of 1.85. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $96.25. The firm's 50 day moving average is $89.73 and its 200 day moving average is $88.03.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.56%. Medtronic's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. Medtronic's dividend payout ratio is presently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.